Esperion Therapeutics Inc (NASDAQ: ESPR) on Friday, soared 0.54% from the previous trading day, before settling in for the closing price of $1.85. Within the past 52 weeks, ESPR’s price has moved between $1.58 and $3.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 9.55% over the last five years. The company achieved an average annual earnings per share of 85.23%. With a float of $195.04 million, this company’s outstanding shares have now reached $195.44 million.
The firm has a total of 240 workers. Let’s measure their productivity. In terms of profitability, gross margin is 81.57%, operating margin of 5.57%, and the pretax margin is -29.37%.
Esperion Therapeutics Inc (ESPR) Insider Activity
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Esperion Therapeutics Inc is 0.99%, while institutional ownership is 66.14%. The most recent insider transaction that took place on Jan 17 ’25, was worth 20. In this transaction Chief Financial Officer of this company sold 9 shares at a rate of $2.27, taking the stock ownership to the 240,682 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Commercial Officer sold 123 for $2.26, making the entire transaction worth $278. This insider now owns 159,998 shares in total.
Esperion Therapeutics Inc (ESPR) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 85.23% per share during the next fiscal year.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
Esperion Therapeutics Inc (ESPR) is currently performing well based on its current performance indicators. A quick ratio of 1.37 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.04 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Analysing the last 5-days average volume posted by the [Esperion Therapeutics Inc, ESPR], we can find that recorded value of 3.12 million was lower than the volume posted last year of 4.82 million. As of the previous 9 days, the stock’s Stochastic %D was 37.80%. Additionally, its Average True Range was 0.15.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 11.86%, which indicates a significant decrease from 27.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.30% in the past 14 days, which was lower than the 87.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.3629, while its 200-day Moving Average is $2.1953. Now, the first resistance to watch is $1.8817. This is followed by the second major resistance level at $1.9033. The third major resistance level sits at $1.9367. If the price goes on to break the first support level at $1.8267, it is likely to go to the next support level at $1.7933. Should the price break the second support level, the third support level stands at $1.7717.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
Market capitalization of the company is 366.49 million based on 197,035K outstanding shares. Right now, sales total 116,330 K and income totals -209,250 K. The company made 51,630 K in profit during its latest quarter, and -29,520 K in sales during its previous quarter.
